Steve Worland has served as our president and chief executive officer and as a member of our board of directors since our inception in May 2012. Previously, Dr. Worland served as chief executive officer of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from August 2007 until its acquisition by Roche Holding AG in 2011. Prior to his appointment as chief executive officer of Anadys Pharmaceuticals, Dr. Worland served as its chief scientific officer and President, Pharmaceuticals. Prior to Anadys Pharmaceuticals, Inc., Dr. Worland was vice president and head of Antiviral Research at Pfizer Inc. and Vice President at WarnerLambert Co., where he was responsible for worldwide anti-infectives strategy. Dr. Worland has served on the board of directors of Tracon Pharmaceuticals, Inc., a biopharmaceutical company, since February 2015. Dr. Worland was an NIH postdoctoral fellow in molecular biology at Harvard University and completed a Ph.D. in chemistry at the University of California, Berkeley. He received his B.S. with Highest Honors in Biological Chemistry from the University of Michigan.